Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 8, 2026Journal of Cardiovascular Pharmacology

Cardiac myosin inhibitors transform obstructive HCM management but remain uncertain for non-obstructive disease.

View Full Paper
Ask AI
Bookmark
Share

Population

Patients with hypertrophic cardiomyopathy (HCM)

Design

Review

Key result

Cardiac myosin inhibitors have transformed the management of obstructive hypertrophic cardiomyopathy, while their role in non-obstructive disease remains uncertain.

Authors

MSMadeline P. SmootJMJames P. MacNamaraMAMichael P. Ayers

Discussion

Loading...

Member takes

Overview

May support targeted HCM therapies in select patients; leaves open need for confirmatory RCTs before practice change.

Key Points

  • The aim is to review the current evidence and innovative therapies in the management of hypertrophic cardiomyopathy (HCM).
  • Systematic review of pharmacology, clinical trial evidence, and safety of cardiac myosin inhibitors (CMIs)
  • Assessment of new therapeutic approaches including myosin modulators and metabolic agents
  • Cardiac myosin inhibitors significantly improved symptom relief and management of obstructive HCM
  • Emerging therapies show potential for broader application across HCM phenotypes, though their efficacy in non-obstructive HCM remains uncertain

Structured PICO

P
Population
Patients with hypertrophic cardiomyopathy (HCM)
I
Intervention
Cardiac myosin inhibitors (CMIs) and emerging targeted therapies (next-generation myosin modulators, metabolic agents, SGLT inhibitors, RNA-targeted approaches)

This review highlights the transformative impact of cardiac myosin inhibitors on obstructive hypertrophic cardiomyopathy and outlines emerging targeted therapies for broader disease modification.

Limitations

  • The role of cardiac myosin inhibitors in non-obstructive HCM disease remains uncertain

Cite This Study

Smoot et al. (2026) conducted a review in Hypertrophic cardiomyopathy (HCM). Cardiac myosin inhibitors (CMIs) was evaluated. Cardiac myosin inhibitors have transformed the management of obstructive hypertrophic cardiomyopathy, while their role in non-obstructive disease remains uncertain.

synapsesocial.com/papers/6a4de8a7d2ea289ef6283357https://doi.org/10.1097/fjc.0000000000001843
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Current and emerging medical and surgical therapy in hypertrophic cardiomyopathy2025
  2. 2Medical Management of Hypertrophic Cardiomyopathy2026
  3. 3Expanding the Role of Myosin Inhibition in Hypertrophic Cardiomyopathy — A Tale of Two Conditions2025 · 2 citations
  4. 4INNOVATIVE DIAGNOSTIC TECHNOLOGIES AND TARGETED THERAPEUTICS IN HYPERTROPHIC CARDIOMYOPATHY: IMPLICATIONS FOR PERSONALIZED PATIENT CARE2025
  5. 5Mechanisms and Therapies of Hypertrophic Cardiomyopathy2025